| Withdrawn | Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at NCT03128489 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers NCT02853929 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ NCT02422264 | GlaxoSmithKline | Phase 4 |
| Completed | Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks o NCT02569879 | GlaxoSmithKline | — |
| Completed | Duration of Protection: GSK DTaP Vaccines NCT02447978 | GlaxoSmithKline | — |
| Completed | Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 a NCT02096263 | GlaxoSmithKline | Phase 3 |
| Completed | Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Childre NCT01988857 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants NCT01890850 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young NCT01738477 | GlaxoSmithKline | Phase 3 |
| Completed | Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers NCT01577732 | GlaxoSmithKline | Phase 3 |
| Completed | Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea NCT01568060 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) V NCT01353703 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/H NCT01453998 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib NCT01449812 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents NCT01362322 | GlaxoSmithKline | Phase 4 |
| Completed | Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/H NCT01358825 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children NCT01245049 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults NCT01323959 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine NCT01309646 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217 NCT01248884 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster NCT01171989 | GlaxoSmithKline | Phase 2 |
| Completed | Evaluation of Boostrix™10 Years After Previous Booster Vaccination NCT01147900 | GlaxoSmithKline | Phase 4 |
| Completed | Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants NCT01090453 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine NCT01086423 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) NCT00964028 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Month NCT00970307 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. NCT00871000 | GlaxoSmithKline | Phase 3 |
| Terminated | Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months NCT00871741 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine i NCT00871117 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine. NCT00835237 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants NCT00753649 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children NCT00696423 | GlaxoSmithKline | Phase 3 |
| Completed | Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Chil NCT00611559 | GlaxoSmithKline | Phase 4 |
| Completed | Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine NCT00635128 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine NCT00627458 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. NCT00610168 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 NCT00548171 | GlaxoSmithKline | Phase 4 |
| Completed | Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial NCT00489970 | GlaxoSmithKline | Phase 3 |
| Completed | Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccin NCT00463437 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine NCT00452686 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTP NCT00412854 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Year NCT00406562 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix i NCT00385255 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age NCT00376779 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Mont NCT00379977 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years NCT00346073 | GlaxoSmithKline | Phase 3 |
| Completed | Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Health NCT00320463 | GlaxoSmithKline | Phase 3 |
| Completed | Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine NCT00297856 | GlaxoSmithKline | — |
| Completed | US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococca NCT00282295 | GlaxoSmithKline | Phase 4 |
| Completed | Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infant NCT00290342 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Sch NCT00316147 | GlaxoSmithKline | Phase 3 |
| Completed | Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjuga NCT00307567 | GlaxoSmithKline | Phase 2 |
| Completed | Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV V NCT00148941 | GlaxoSmithKline | Phase 3 |
| Completed | Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Health NCT00325156 | GlaxoSmithKline | Phase 4 |
| Completed | Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis NCT00325143 | GlaxoSmithKline | Phase 3 |
| Completed | Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunog NCT00263679 | GlaxoSmithKline | Phase 3 |
| Completed | Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccinati NCT01457547 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months NCT00352963 | GlaxoSmithKline | Phase 3 |
| Completed | Post Market Surveillance for Infanrix™ NCT00908115 | GlaxoSmithKline | — |
| Terminated | Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccin NCT00544271 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) NCT01294605 | GlaxoSmithKline | Phase 4 |
| Completed | Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine NCT00146835 | GlaxoSmithKline | — |
| Completed | Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in NCT00263692 | GlaxoSmithKline | Phase 2 |
| Completed | A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine NCT00109330 | GlaxoSmithKline | Phase 3 |
| Completed | Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactiv NCT01277705 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infa NCT00879827 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vacc NCT01457560 | GlaxoSmithKline | Phase 3 |